Anti-JAK1 Antibody, clone 73

Control
Huvec cell lysate, whole Jurkat cell lysate

Routinely evaluated by Western Blot on Huvec lysates.

Western Blot Analysis: 1:500 dilution of this lot detected JAK1 on 10 μg of Huvec lysates.

Anti-JAK1 Antibody, clone 73 detects level of JAK1 & has been published & validated for use in WB, IP & IF.

Immunoprecipitation: A previous lot of this antibody was used in immunoprecipitation under native and denatured conditions.

Immunofluorescence: A previous lot of this antibody was used in IF.
Optimal working dilutions must be determined by end user.

Recognizes JAK1 (Janus Kinase 1). The members of the JAK family of cytoplasmic protein tyrosine kinases physically associate with ligand-bound receptors. It is this association that results in tyrosine phosphorylation and activation. JAK1 is approximately 130 kDa and contains a C-terminal tyrosine kinase domain, an adjacent kinase or kinase-related domain, and five other domains that are highly conserved among JAK family members.

130 kDa

JAKs are non-receptor tyrosine kinases which couple to cytokine receptors, and are activated by cytokines. They regulate a spectrum of cellular functions downstream of activated cytokine receptors in the lympho-hematopoietic system. JAK kinases (JAK1, JAK2, JAK3, Tyk2) have a kinase domain and a second, pseudokinase domain which is not enzymatically active. The principal effectors of JAKs are the STATs (Signal Transducers and Activators of Transcription), which are direct activators of transcription, but JAKs also signal to the Ras-MAP Kinase pathway, and through Tec, to the PI3 Kinase pathway. Immunological stimuli, such as interferons and cytokines, induce recruitment of STAT transcription factors to cytokine receptor-associated JAK2. JAK2 then phosphorylates proximal STAT transcription factors, which subsequently dimerize and translocate to the nucleus where they bind DNA. The canonical JAK/Stat pathway is integral to maintaining a normal immune system by stimulating proliferation, differentiation, survival and host resistance to pathogens. Altering JAK/Stat signaling to reduce cytokine induced pro-inflammatory responses represents an attractive target for anti-inflammatory therapies. Within the JAK2 kinase domain, there is a region that has considerable sequence homology to the regulatory region of the insulin receptor. Among a variety of sites, Tyrosines 1007 and 1008 (Tyr1007/1008) are sites of trans- or autophosphorylation in vivo and in vitro kinase reactions. JAK2 is required for signaling through a different subset of cytokine receptors, while JAK1 is essential for signaling from the IL-2, IL-6 and interferon receptors. JAK3 is required for signaling through cytokine receptors which share a common gamma-chain.

Generated from human JAK1, amino acids 551-776.

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

Replaces: MAB3700

Format: Purified

Purified mouse monoclonal IgG2b aqueous buffered solution containing 50% glycerol, BSA, and <0.09% sodium azide

Stable frozen at -20°C in undiluted aliquots for up to 1 year from date of receipt.
Handling Recommendations: Upon first thaw, and prior to removing the cap, centrifuge the vial and gently mix the solution. Aliquot into microcentrifuge tubes and store at -20°C. Avoid repeated freeze/thaw cycles, which may damage IgG and affect product performance. Note: Variability in freezer temperatures below -20°C may cause glycerol containing solutions to become frozen during storage.